Wells Fargo & Company Aerie Pharmaceuticals Inc Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $956,895 - $2.29 Million	150,219 Added 775.64%	169,586 $2.57 Million
Q2 2022 Aug 12, 2022	SELL	$4.95 - $9.16 $47,074 - $87,111	-9,510 Reduced 32.93%	19,367 $145,000
Q1 2022 May 16, 2022	SELL	$5.64 - $9.8 $212,402 - $369,068	-37,660 Reduced 56.6%	28,877 $263,000
Q4 2021 Feb 14, 2022	BUY	$7.02 - $13.33 $78,097 - $148,296	11,125 Added 20.08%	66,537 $468,000
Q3 2021 Nov 15, 2021	BUY	$11.32 - $16.63 $463,520 - $680,948	40,947 Added 283.08%	55,412 $632,000
Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $96,720 - $121,028	6,380 Added 78.91%	14,465 $232,000
Q1 2021 May 13, 2021	SELL	$13.12 - $20.9 $937,345 - $1.49 Million	-71,444 Reduced 89.83%	8,085 $145,000
Q4 2020 Feb 09, 2021	BUY	$9.12 - $14.49 $531,084 - $843,796	58,233 Added 273.45%	79,529 $1.07 Million
Q3 2020 Nov 05, 2020	SELL	$10.46 - $14.46 $113,103 - $156,355	-10,813 Reduced 33.68%	21,296 $251,000
Q2 2020 Aug 13, 2020	BUY	$12.0 - $16.13 $88,716 - $119,249	7,393 Added 29.91%	32,109 $474,000
Q1 2020 May 14, 2020	BUY	$11.84 - $25.52 $292,637 - $630,752	24,716 New	24,716 $334,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.